128 related articles for article (PubMed ID: 14751331)
1. Tuberculosis prevention in Mexican immigrants: limitations of short-course therapy.
Kandula NR; Dworkin MS; Carroll MR; Lauderdale DS
Am J Prev Med; 2004 Feb; 26(2):163-6. PubMed ID: 14751331
[TBL] [Abstract][Full Text] [Related]
2. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Aug; 50(34):733-5. PubMed ID: 11787580
[TBL] [Abstract][Full Text] [Related]
3. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
Jasmer RM; Daley CL
Am J Respir Crit Care Med; 2003 Mar; 167(6):809-10. PubMed ID: 12623855
[No Abstract] [Full Text] [Related]
4. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
[TBL] [Abstract][Full Text] [Related]
5. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
Kunimoto D; Warman A; Beckon A; Doering D; Melenka L
Clin Infect Dis; 2003 Jun; 36(12):e158-61. PubMed ID: 12802781
[TBL] [Abstract][Full Text] [Related]
6. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
McNeill L; Allen M; Estrada C; Cook P
Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
[TBL] [Abstract][Full Text] [Related]
7. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
Stout JE; Engemann JJ; Cheng AC; Fortenberry ER; Hamilton CD
Am J Respir Crit Care Med; 2003 Mar; 167(6):824-7. PubMed ID: 12446275
[TBL] [Abstract][Full Text] [Related]
8. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Apr; 50(15):289-91. PubMed ID: 11330495
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.
Lee AM; Mennone JZ; Jones RC; Paul WS
Int J Tuberc Lung Dis; 2002 Nov; 6(11):995-1000. PubMed ID: 12475146
[TBL] [Abstract][Full Text] [Related]
10. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.
Reichman LB; Lardizabal A; Hayden CH
Am J Respir Crit Care Med; 2004 Oct; 170(8):832-5. PubMed ID: 15297274
[No Abstract] [Full Text] [Related]
11. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
12. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
Cook PP; Maldonado RA; Yarnell CT; Holbert D
Clin Infect Dis; 2006 Aug; 43(3):271-5. PubMed ID: 16804838
[TBL] [Abstract][Full Text] [Related]
13. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
[TBL] [Abstract][Full Text] [Related]
14. From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
JAMA; 2002 Dec; 288(23):2967. PubMed ID: 12492097
[No Abstract] [Full Text] [Related]
15. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
[TBL] [Abstract][Full Text] [Related]
16. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
[No Abstract] [Full Text] [Related]
17. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction.
Khokhar O; Gange C; Clement S; Lewis J
Dig Dis Sci; 2005 Jan; 50(1):207-11. PubMed ID: 15712662
[No Abstract] [Full Text] [Related]
19. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
[TBL] [Abstract][Full Text] [Related]
20. Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation.
Ichai P; Saliba F; Antoun F; Azoulay D; Sebagh M; Antonini TM; Escaut L; Delvart V; Castaing D; Samuel D
Liver Transpl; 2010 Oct; 16(10):1136-46. PubMed ID: 20879012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
